[One-year persistence of renin-angiotensin-aldosterone system inhibitors fixed drug combinations in hypertensive patients].

Gábor Simonyi,Tamás Ferenci, Ervin Finta,Mihály Medvegy,István Wittmann

Orvosi hetilap（2023）

引用 0|浏览5

暂无评分

摘要

The authors have demonstrated that the one-year persistence of RAAS inhibitor FDCs varies significantly in hypertensive patients. ACE inhibitor/CCB FDCs were found to be the most advantageous. Orv Hetil. 2023; 164(34): 1337-1341.

查看译文

关键词

adherence, persistence, antihypertensive therapy, RAAS inhibitor FDCs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要